AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with COPD.
The product will be tested in COPD patients with heightened cardiovascular risk, regardless of exacerbation history, AstraZeneca added.
Breztri Aerosphere is a triple combination therapy comprised of budesonide, glycopyrronium and formoterol fumarate. The combination, also called BGF, is already approved for the treatment of COPD in 75 countries, including the U.S., EU, China and Japan.
AstraZeneca added that it has also dosed the first patients in a Phase 3 study evaluating the impact of Breztri on integrated cardiopulmonary parameters associated with health and survival in COPD patients.